Pharma 'It was a good lesson': FDA reconsiders CAR-T boxed warning on secondary cancers, Peter Marks says

An FDA announcement last year of an investigation into the risk of patients developing secondary cancers following the treatment of CAR-T cell therapies sent shock waves across the industry. The probe led to classwide black boxed warnings on existing CAR-T products’ labels.